Fenproporex

Summary

Fenproporex (CHEMBL2105566) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 188.27 Da · C12H16N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105566
Name	Fenproporex
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	61810
Molecular formula	C12H16N2
Molecular weight	188.27
InChIKey	IQUFSXIQAFPIMR-UHFFFAOYSA-N

SMILES: CC(CC1=CC=CC=C1)NCCC#N

IUPAC name: 3-(1-phenylpropan-2-ylamino)propanenitrile

Also known as: Femproporex, Fenorex, Fenproporex, J268.797F, FENPROPOREX

Patent coverage: 586 distinct patent families (2,438 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).